TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01613248
Drug: Placebo-matching MK-1602
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single administration of placebo-matching MK-1602 taken at onset of migraine of moderate or severe intensity. Dosage form is film coated tablet for oral administration. Dose is provided to participants as a blinded bottle of tablets packaged to achieve placebo study medication. Participants will be instructed to take all study medication from the bottle when they treat their migraine headache.
Study: NCT01613248
Drug: Rescue medication
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: If moderate or severe migraine headache pain continues 2 hours after dose of study medication or if migraine headache comes back within 48 hours,~Participants will be allowed to take their own rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\]), anti-emetics, triptans or other medication not explicitly excluded.
Study: NCT00123916
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: a dose calculated as 5mg/kg/day for 60 days, now administered as a fixed daily dose of 300mg during 40 - 80 days of treatment - period adjusted according to the patient's body weight to a total minimum dose of 12g (corresponding to 40kg) and a total maximum dose of 24g (corresponding to 80kg)
Study: NCT00275925
Drug: Oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01426191
Drug: xinzhijun
Approvals — FDA: no, EMA: no, PMDA: no
Description: durg:Cefotaxime sodium and sulbactam sodium for injection(2:1)~1.5-3.0g,iv,bid or tid for 5-12 days;~Serious infections:1.0-1.5g,iv,tid or qid for 5-12 days
Study: NCT00769366
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy after Acute myocardial infarction
Study: NCT03713593
Drug: saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as an IV infusion on Day 1 Q3W
Study: NCT03447769
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered subcutaneously on day 1 of every 21-day cycle for 18 cycles. Placebo solution for injection was provided by Novartis as ready-to-use pre-filled syringes to be administered by study personnel.
Study: NCT02758431
Drug: Placebo Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel packet applied daily for 28 days.
Study: NCT02758431
Drug: Placebo Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablet taken daily for 28 days.
Study: NCT02758431
Drug: Testosterone Gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone Gel applied daily for 28 days
Study: NCT04642638
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile saline sodium citrate (SSC) buffer (SSC-0001) was administered ID on Day 0 and Day 28.
Study: NCT00003269
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00775749
Drug: placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo patch will be applied to the right upper back prior to surgery. It will be covered with an opaque bandage to minimize inadvertent removal and conceal which patch has been placed.
Study: NCT00216684
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00736866
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of Acetylcysteine: every 12 hours PO, for a total of 4 doses. Treatment is to be started 12 hours before angiography, that is, two doses should be administered before it. When this is not achievable, at least one dose should be administered before angiography.
Study: NCT02722746
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive epinephrine in their epidural block infusion during the procedure. The amount of epinephrine provided during the procedure will be based on the group assignment.
Study: NCT00439959
Drug: GSK625433/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02997358
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m² Day 1 of each 3-weeks cycle
Study: NCT04580394
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration before bed
Study: NCT01531751
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy will be based on alchilators, proteasome inhibitors, steroids, IMiDs.
Study: NCT01793519
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT03198000
Drug: F# 13418-148 Eye Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: ocular clear liquid. Tetrahydrozoline 0.05%; Glycerin 0.40% 1-2 drops will be instilled as instructed over one day
Study: NCT03198000
Drug: F#13418-158 Eye Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: ocular clear liquid Tetrahydrozoline 0.05%; Glycerin 0.20%, Hypromellose 0.2%, Polyethylene glycol 400 1.0% 1-2 drops will be instilled as instructed over one day
Study: NCT03198000
Drug: F# PF-004390 Eye Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocular clear liquid Tetrahydrozoline 0.05%; 1-2 drops will be instilled as instructed over one day
Study: NCT01316822
Drug: ARRY-382, cFMS inhibitor; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple dose, escalating
Study: NCT02176395
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
Study: NCT02626715
Drug: Reduced-Intensity Conditioning Regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Campath (alemtuzumab) - drug class: monoclonal antibody Droxia (hydroxyurea) - drug class: antimetabolite Fludara (fludarabine) - drug class: antimetabolite Alkeran (melphalan) - drug class: alkylating agent Thiotepa (triethylenethiophosphoramide) - drug class: cytotoxic agent
Study: NCT02626715
Drug: Myeloablative Conditioning Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Campath (alemtuzumab) - drug class: monoclonal antibody Thiotepa (triethylenethiophosphoramide) - drug class: cytotoxic agent Fludara (fludarabine) - drug class: antimetabolite Busulfex (busulfan) - drug class: alkylating agent
Study: NCT03877718
Drug: Arm 1: CL-H1T
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine HCl 18.75 mg)
Study: NCT03877718
Drug: Arm 2: CL-H1T
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine HCl 37.5 mg)
Study: NCT01985126
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 to 1000 mg administered in prophylactic doses by mouth prior to study drug administration.
Study: NCT00833989
Drug: GSK249320
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V. infusion
Study: NCT00833989
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03825380
Drug: Lumigan®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eyedrops
Study: NCT02532660
Drug: LABCAT TCJUSS
Approvals — FDA: no, EMA: no, PMDA: no
Description: LABCAT TCJUSS 1000mg daily (two 250mg capsules in the morning + 2 capsules of 250 mg at night)
Study: NCT02532660
Drug: LABCAT TCJUSS Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: LABCAT TCJUSS placebo daily (2 capsules in the morning + 2 capsules at night);
Study: NCT03399175
Drug: Early high-dose corticosteroid and immunosuppressive therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early high-dose corticosteroid and immunosuppressive therapy
Study: NCT02458690
Drug: Antidepressant Medications
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: The IMPACT treatment manual provides guidelines for using antidepressants, such as selecting a medication, titrating, switching to another medication, managing side effects, and avoiding drug interactions. To optimize eIMPACT for CVD risk reduction, we have restricted the IMPACT list of antidepressants to SSRIs (sertraline, escitalopram, paroxetine, fluoxetine, citalopram), duloxetine, bupropion, and mirtazapine. These medications are FDA approved for the treatment of depression and are the safest from a cardiovascular perspective.
Study: NCT02310828
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo capsule matching Acetium for oral administration.
Study: NCT01555125
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects who were on placebo at Week 52 cannot continue in the extension treatment period
Study: NCT01592890
Drug: RO4917523
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[13C\]-labeled RO4917523, single intravenous tracer dose
Study: NCT02450994
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00029991
Drug: Gingko Biloba (Herb)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03387852
Drug: SAR440340
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for Injection, Route of administration: SC
Study: NCT03387852
Drug: Placebo for SAR440340
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for Injection, Route of administration: SC
Study: NCT02596451
Drug: Diclofenac Sodium gel, 1%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02596451
Drug: Voltaren® Gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02596451
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02133846
Drug: TPI 287 2 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.Drug: Placebo Drug: Placebo 500mL 0.9% sodium chloride.
Study: NCT02133846
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mL 0.9% sodium chloride
Study: NCT01028573
Drug: PEG-ELS (Golytely)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4L consumed evening before colonoscopy
Study: NCT01028573
Drug: PEG-ELS (Golytely)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2L consumed on the evening before and 2L consumed on the morning of Colonoscopy
Study: NCT01255046
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tab/tid for 72 weeks
Study: NCT06484439
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg PO q 6h scheduled
Study: NCT06484439
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg q 6h scheduled
Study: NCT06484439
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg PO scheduled q6h
Study: NCT06484439
Drug: Hydrocodone
Normalized name: Hydrocodone
DrugBank: Hydrocodone (DB00956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg hydrocodone PO PRN q6h
Study: NCT02902744
Drug: ILUVIEN®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive Iluvien as the standard of care treatment for diabetic macular edema.
Study: NCT00609739
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX will be administered to recipients of non-genotypically identical BMT. MTX will be administered at a dose of 15 mg/m\^2 (based on adjusted ideal body weight) intravenously (IV) on day +1 and at a dose of 10 mg/m\^2 IV on days +3, +6, and +11.
Study: NCT00621855
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched placebo
Study: NCT00193700
Drug: Testosterone Gel (1%)
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02303964
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline will be administered to polytrauma subjects randomized to normal saline arm of study
Study: NCT00493766
Drug: LBH589
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01055366
Drug: Elazop (Azarga)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer one drop of ELAZOP in treated eye(s) twice a day for up to 12 weeks
Study: NCT02352948
Drug: MEDI4736 (durvalumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI4736 (durvalumab) treatment by intravenous infusion
Study: NCT00354874
Drug: GW642444
Approvals — FDA: no, EMA: no, PMDA: no
Description: drug
Study: NCT00354874
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01781572
Drug: LEE011
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEE011 will be administered orally once daily
Study: NCT01781572
Drug: MEK162
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEK162 will be administered orally twice daily
Study: NCT02289300
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The assignment will be as follows:~Placebo: 4 matched placebo, t.i.d., orally.~Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) \* 8 cycles)
Study: NCT02289300
Drug: DCB-BO1202+Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The assignment will be as follows:~(Each DCB-BO1202 300mg capsule contains 150mg active ingredient)~DCB-BO1202+Placebo: 2 DCB-BO1202 300mg capsules plus 2 matched placebo, t.i.d., orally.~Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) \* 8 cycles)
Study: NCT01325168
Drug: placebo nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: nasal placebo - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
Study: NCT04094727
Drug: Presumptive treatment with Artemether-lumefantrine (AL)
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All eligible HRPs will be presumptively treated with artemether-lumefantrine (AL) at two timepoints, separated by at least one month. All individuals who have provided informed consent, meet eligibility criteria, are not pregnant or breastfeeding, and who do not have symptoms associated with severe malaria or another severe illness, will be offered an age-appropriate course of AL (age-specific blister packages). AL is currently the first line drug used for uncomplicated malaria in Namibia, and has been used previously in northern Namibia for focal mass drug administration and has no severe adverse effects and is well-tolerated, with high adherence and acceptability in this context. AL requires two daily doses for three consecutive days, for a total of six doses. The first antimalarial dose will be delivered by directly observed therapy (DOT) and subsequent doses will be left with the subject, with instructions to self-administer them.
Study: NCT03731364
Drug: CA-008
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg CA-008 (0.05 mg/mL), 10 mg CA-008 (0.1 mg/mL) and 15 mg CA-008 (0.15 mg/mL)
Study: NCT03731364
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00125190
Drug: rhIGF-1 (mecasermin) for a period of 86 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a day rhIGF-1 injections
Study: NCT03927508
Drug: r-tPA
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse spray and infusion
Study: NCT03780556
Drug: Lornoxicam and mepridine
Normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: compare the effect of each to control pain
Study: NCT00334932
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01771198
Drug: SIMVASTATIN
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SIMVASTATIN tablet of 40mg once a day during 30 days
Study: NCT01934192
Drug: GSK962040 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK962040 50 mg will be administered once daily enteral dose through NG tube up to 7 days.
Study: NCT01934192
Drug: Placebo IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered IV every 6 hours
Study: NCT01760824
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20mg bid for 10 days, amoxicillin 1g bid for first 5 days, clarithromycin 500mg bid for last 5 days and metronidazole 400mg qid for last 5 days
Study: NCT01760824
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20mg bid, metronidazole 400mg qid, bismuth sub citrate 120mg qid and tetracycline 500mg qid, all for 10 days
Study: NCT03396250
Drug: Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve, PMBAY98-7111)
Normalized name: naproxen and diphenhydramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 tablets)
Study: NCT01006863
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing either saline 0.9% solution \[group 1 (n=30)\], ephedrine 0.7 mg/mL \[group 2 (n=30)\], ephedrine 1 mg/mL \[group 3 (n=30)\] or ephedrine 1.5 mg/mL \[group 4 (n=30)\]or phenylephrine 15 mcg/mL \[group 5 (n=30)\]. All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo and the ephedrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
Study: NCT04208763
Drug: Tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inj Tigecycline 100mg stat f/b 50mg i.v. OD
Study: NCT00760838
Drug: Azithromycin 250 mg
Normalized name: azithromycin 250 MG
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 250 mg three times a week during treatment period (6 months); run-in period of 2 weeks; wash-out period of 4 weeks
Study: NCT00760838
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo three times a week during treatment period (6 months); run-in period of 2 weeks; wash-out period of 4 weeks
Study: NCT00915551
Drug: PEP005 (Ingenol Mebutate) gel, 0.015%
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily for 3 consecutive days
Study: NCT00915551
Drug: Vehicle Gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily for 3 consecutive days
Study: NCT02999633
Drug: acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:pills Route of administration: oral
Study: NCT03230916
Drug: IMI/REL FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMI/REL is supplied as a single fixed dose combination (FDC) vial; which is administered at a maximum dose of 15 mg/kg IMI and 15 mg/kg CIL (up to 500 mg IMI and 500 mg CIL) and 7.5 mg/kg REL (up to 250 mg REL).
Study: NCT01697293
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01697293
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02075593
Drug: DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: The DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablet is a purple, oval, biconvex tablets. The tablet contains 52.6 mg DTG sodium which is equivalent to 50 mg DTG free acid, 702 mg ABC sulphate which is equivalent to 600 mg ABC and 300 mg 3TC.
Study: NCT02220972
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00127504
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00929734
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10mg tablets, once daily in three months
Study: NCT00929734
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet, once daily in three months
Study: NCT02247505
Drug: Harnal-D Cap. 0.2mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02247505
Drug: Cialis Tab. 5mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00548769
Drug: Formulation A
Normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation A will contain firategrast drug substance from native drug batch Irvine. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.1 square meter per gram. The tablets will be administered with 240 milliliters of water.
Study: NCT00548769
Drug: Formulation B
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation B will contain firategrast drug substance from native drug batch Tonbridge. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.6 square meter per gram. The tablets will be administered with 240 milliliters of water.
Study: NCT00548769
Drug: Formulation D
Normalized name: Complete Formulation D3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation D will contain firategrast drug substance from Tonbridge with reduced tablet size. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.6 square meter per gram. The tablets will be administered with 240 milliliters of water.
Study: NCT01253421
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single-dose placebo capsule
Study: NCT02711215
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8mg citalopram or placebo (saline) will be applied during PET/MR measurements in a double-blind randomized cross-over design
Study: NCT01525927
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for three cycles prior to radiotherapy